JoVE Logo

Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Results
  • Discussion
  • Disclosures
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

This manuscript describes an ex vivo model system comprised of organ-conditioned media derived from the lymph node, bone, lung, and brain of mice. This model system can be used to identify and study organ-derived soluble factors and their effects on the organ tropism and metastatic behavior of cancer cells.

Abstract

Breast cancer preferentially metastasizes to the lymph node, bone, lung, brain and liver in breast cancer patients. Previous research efforts have focused on identifying factors inherent to breast cancer cells that are responsible for this observed metastatic pattern (termed organ tropism), however much less is known about factors present within specific organs that contribute to this process. This is in part because of a lack of in vitro model systems that accurately recapitulate the organ microenvironment. To address this, an ex vivo model system has been established that allows for the study of soluble factors present within different organ microenvironments. This model consists of generating conditioned media from organs (lymph node, bone, lung, and brain) isolated from normal athymic nude mice. The model system has been validated by demonstrating that different breast cancer cell lines display cell-line specific and organ-specific malignant behavior in response to organ-conditioned media that corresponds to their in vivo metastatic potential. This model system can be used to identify and evaluate specific organ-derived soluble factors that may play a role in the metastatic behavior of breast and other types of cancer cells, including influences on growth, migration, stem-like behavior, and gene expression, as well as the identification of potential new therapeutic targets for cancer. This is the first ex vivo model system that can be used to study organ-specific metastatic behavior in detail and evaluate the role of specific organ-derived soluble factors in driving the process of cancer metastasis.

Introduction

Breast cancer is the most frequently diagnosed cancer in women and the second leading cause of cancer-related deaths1. Breast cancer's high mortality rate is mainly due to the failure of conventional therapy to mitigate and eliminate metastatic disease; approximately 90% of cancer-related deaths are due to metastasis2. Understanding the underlying molecular mechanisms of the metastatic cascade is paramount to the development of therapeutics effective in both early and late-stage breast cancer.

Past research has helped elucidate the multistep nature of breast cancer metastasis and it is hypothesized that the outcome of both cancer progression and metastasis is largely dependent upon interactions between cancer cells and the host environment3. Clinical observations indicate that many cancers display organ tropism, i.e., the tendency to preferentially metastasize to specific organs.In the case of breast cancer, a patient's disease typically spreads or metastasizes to 5 main sites, including the bone, lungs, lymph node, liver, and brain4-6. Many theories have been developed to explain this process, but only a few have withstood the test of time. Ewing's theory of metastasis, proposed in the 1920s, hypothesized thatthe distribution of metastasis was strictly due to mechanical factors; whereby tumor cells are carried throughout the body by normal defined physiological blood flow patterns and simply arrest in the first capillary bed they encounter7. In contrast, Stephen Paget's 1889 "seed and soil" hypothesis suggested that additional molecular interactions were responsible for survival and growth of metastases, whereby cancer cells ("seeds") can only establish themselves and proliferatein organ microenvironments that produce appropriate molecular factors ("soil")8. Almost a century later, Leonard Weiss undertook a meta-analysis of previously published autopsy data and confirmed Ewing's prediction that many metastatic tumors detected at the time of autopsy were found in the anticipated proportions that would be expected if metastatic organ tropism was determined by blood flow patterns alone. However, in manyinstances there were fewer or more metastases formed at certain sites then would be expected by Ewing's proposed mechanical factors9. These accounts and theories suggest that specific organ microenvironments play a critical role in the dissemination patterns and subsequent growth and survival of many cancers, including breast cancer.

Past research efforts have mainly focused on tumor-cell derived factors and their contribution to the organ tropism observed in breast cancer metastasis10-12, however little research has explored factors derived from the organ microenvironment that may provide a favorable niche for the establishment of breast cancer metastases. This is largely attributable to the technical challenges of studying components of the organ microenvironment in vitro.

The current article describes a comprehensive ex vivo model system for studying the influence of soluble components of the lymph node, bone, lung, and brain on the metastatic behavior of human breast cancer cells. Previous studies have validated this model system by demonstrating that different breast cancer cell lines display cell-line specific and organ-specific malignant behavior in response to organ-conditioned media that corresponds to their in vivo metastatic potential13. This model system can be used to identify and evaluate specific organ-derived soluble factors that may play a role in the metastatic behavior of breast and other types of cancer cells, including influences on growth, migration, stem-like behavior, and gene expression, as well as the identification of potential new therapeutic targets for cancer. This is the first ex vivo model system that can be used to study organ-specific metastatic behavior in detail and to evaluate the role of organ-derived soluble factors in driving the process of cancer metastasis.

Protocol

All animal studies were conducted in accordance with the recommendations of the Canadian Council on Animal Care, under protocols approved by the Western University Animal Use Subcommittee.

1. Organ Isolation (Lung, Brain, Bone, Lymph Node)

  1. Prepare four sterile 50 ml conical tubes (one for each organ to be isolated) containing approximately 30 ml of sterile phosphate-buffered saline (PBS). Pre-weigh each tube of PBS using an electronic balance.
  2. Euthanize 6-12 week old mouse by CO2 inhalation. Mice should be left in the CO2 chamber for approximately 1 - 2 min or until the mouse stops moving and breathing. Successful euthanasia can be further confirmed by a lack of heartbeat when checked manually with a finger. Avoid cervical dislocation as this method may rupture blood vessels of the neck leading to difficulty removing axillary lymph nodes.
    Note: Previous work has specifically used healthy female nude mice, Hsd:Athymic Nude-Foxn1nu13.
  3. In a sterile tissue culture hood, place the mouse on its back on a polystyrene foam pad, spread the limbs and use pins to keep them in place.
  4. Using sterile forceps and scissors, cut the abdominal skin at the midline at the genitalia and cut upwards toward the mouth. Gently pull back the abdominal skin from the abdominal muscles and pin in place on the polystyrene foam pad.
  5. Locate the axillary, brachial, and inguinal lymph nodes.
    Note: Lymph nodes are usually surrounded by fatty tissue. The inguinal lymph nodes are the easiest to locate as they are found superficially at the junction of two blood vessels on the pulled back abdominal skin. Axillary and brachial lymph nodes are located deeper within the tissue and require gentle maneuvering of tissue.
    1. After you have located the lymph nodes, use the scissors to gently and carefully cut the lymph nodes away from the skin, fat and vessels and remove them from the mouse. To confirm proper dissection, roll the forceps over the removed tissue. If a hard lump exists when rolling the forceps over the tissue, then a lymph node has likely been removed successfully.
    2. Place removed lymph nodes in ice cold PBS.
  6. Using the forceps and scissors, open the abdominal cavity by cutting through the exposed abdominal wall in an upward motion towards the chest. Carefully cut through the sternum, exposing the thoracic cavity.
  7. Locate the diaphragm below the lungs and cut the diaphragm. It should pull towards the ribs due to tension.
  8. Lift the lungs from underneath and cut the underlying tissue towards the trachea. This allows the lungs to be removed freely from the thoracic cavity. Remove the heart and lungs en bloc and place in ice cold PBS. The heart can be removed from the lungs here or just before weighing in Step 2.
  9. Remove the pins, keeping the mouse in place on the polystyrene foam pad. Turn the mouse over and cut the skin of the lower back all the way across from flank to flank.
  10. Using a sterile piece of gauze to hold the torso of the mouse, peel the back skin of the mouse over the legs and feet of the mouse.
  11. Using the same piece of sterile gauze, hold the lower leg in place, carefully break the ankle joint of the mouse foot and peel the skin over the joint proximally towards the knee joint.
  12. Using scissors, remove the tibia free from the knee joint and place in ice cold PBS.
  13. Repeat steps 1.11) to 1.12) with opposite limb.
  14. Using forceps, hold the femur in place, cut away surrounding muscle tissue using the scissors and remove the femur, placing it in ice cold PBS.
  15. Repeat step 1.14) with opposite limb.
  16. Using a new piece of sterile gauze, hold the head of the mouse in place. Using forceps and scissors, gently remove the skin to expose the skull. Using scissors, carefully cut the occipital skull from the top center in a straight and downward line to expose the posterior brain.
  17. Using forceps, scoop underneath the brain towards the anterior and remove the whole brain. Place the brain in ice cold PBS.
  18. Repeat steps 1.1) to 1.17) for at least four mice.

2. Organ Weighing

  1. Following organ isolation, weigh each PBS tube containing lung and brain tissue using an electronic balance.
  2. Calculate the weight difference by subtracting the pre-isolation weight (PBS only) from the weight of the PBS tube + organs (lung and brain).
  3. Determine the amount of media needed to resuspend tissue fragments from the calculated weight difference.
    Note: Lung and brain tissue are weight normalized by resuspension in a 4:1 media:tissue ratio (vol/wt).

3. Generation of Lung- and Brain- Conditioned Media

  1. In a sterile tissue culture hood, invert PBS tubes containing lung or brain three times to remove residual blood from organs and aspirate PBS containing blood. Repeat with fresh cold PBS until solution appears clear with no evidence of blood.
  2. Place lungs and brains in separate 60 mm2 glass petri dishes. Using two sterile scalpel blades, mince lungs or brains by repeatedly slicing back and forth until tissue fragments are approximately ~ 1 mm3 in size.
  3. Resuspend tissue fragments in appropriate volume (determined previously in step 2.3) of Dulbecco's Modified Eagle's Medium (DMEM):F12 media supplemented with 1x concentrated mitogen supplement and penicillin (50 µg/ml)/streptomycin (50 µg/ml).
  4. Add resuspended lung or brain tissue fragments to one well of a 6-well plate.
  5. Incubate tissue fragments in media for 24 hr at 37 °C and 5% CO2. Following incubation, collect conditioned media for each tissue and further dilute by adding three equivalent volumes of fresh media in a 50 ml conical tube.
  6. Centrifuge at 1,000 x g in diluted conditioned media for each organ at 4 °C for 15 min to remove large tissue debris. Collect media supernatant and filter through a 0.22 µm syringe filter.
  7. Pool conditioned media from each organ (i.e., lung with lung and brain with brain) from multiple mice to account for mouse-to-mouse variability. Aliquot and store conditioned media at -80 °C until use.

4. Generation of Bone Marrow-conditioned Media

  1. In a sterile tissue culture hood, trim excess tissue from the bone and remove epiphyses (end pieces) from the bones with scissors.
  2. Using a 27 ½ G needle, flush medullary cavity of bones by pushing 1 ml of PBS through the center of each bone. This will allow you to collect bone marrow stromal cells (BMSC)into a fresh tube containing PBS.
  3. Centrifuge at 1,000 x g for 5 min at 4 °C and wash BMSC twice with PBS. Resuspend bone marrow stromal cells in 20 ml of bone stromal cell growth media (DMEM:F12 media supplemented with 1x concentrated mitogen supplement, penicillin (50 µg/ml)/streptomycin (50 µg/ml) and 10% fetal boven serum (FBS)).
  4. Plate 10 ml of resuspended bone marrow stromal cells in one T75 flask.
    Note: Combine and plate cells from every 2 mice in each T75 flask; for four mice, two T75 flasks are needed (approximately 1 x 107 cells/flask).
  5. Incubate bone marrow stromal cells in bone stromal cell growth media for 24 hr at 37 °C and 5% CO2. Following incubation, remove media from both T75 flasks and put into new T75 flask, label this flask as "Floater Flask". Add fresh bone stromal cell growth media to previous 2 flasks and incubate all 3 flasks at 37 °C and 5% CO2.
  6. After cells reach approximately 70% confluency (approximately 5 - 7 days) passage cells. To do this, remove medium and wash cells twice with PBS (3 ml each wash). Remove PBS and add 3 ml of trypsin/EDTA solution, ensuring that trypsin covers the entire surface of the flask. After cells lift off the flask (~ 2 - 3 min), stop trypsinization reaction by adding 3 ml bone stromal cell growth media). Centrifuge 900 x g for 5 min at 4 °C, discard media, and resuspend cells in 10 ml of fresh bone stromal cell growth media.
  7. Pool cells from all flasks and passage 1:5 into three new T75 flasks and incubate at 37 °C and 5% CO2. After cells once again reach 70%, repeat step 4.6 and pool and passage all adherent cells a second time. Re-plate all cells to four T75 flasks and incubate 37 °C and 5% CO2. Bone stromal cell growth media should be used for all steps.
  8. Allow cells to reach confluence, wash cells three times with PBS and add bone stromal cell collection media (DMEM:F12 media + 1x concentrated mitogen supplement + penicillin (50 µg/ml)/streptomycin (50 µg/ml); 10 ml/T75), making sure that this media is free of FBS. Collect bone marrow-conditioned media 72 hr later, filter through a 0.22 µm filter, pool, aliquot, and store at -80 °C until use.
  9. If desired, confirm the phenotype of the isolated bone marrow stromal cells (BMSC) using antibodies against mouse Sca-1, CD105, CD29, and CD73, CD44, using standard flow cytometry techniques as described previously13.

5. Generation of Lymph Node-conditioned Media

  1. In a sterile tissue culture hood, invert PBS tube containing lymph nodes three times to remove residual blood from lymph nodes and aspirate bloody PBS. Repeat with fresh cold PBS until solution appears clear with no evidence of blood.
  2. Place lymph nodes in 60 mm2 glass petri dishes. Using two sterile scalpel blades, mince lymph nodes by repeatedly slicing back and forth until tissue fragments are approximately 1 mm3 in size.
  3. In a conical tube, resuspend tissue fragments in 10 ml of Roswell Park Memorial Institute 1640 (RPMI1640) media supplemented with penicillin (50 µg/ml)/streptomycin (50 µg/ml), 5 x 10-5 M sterile β-mercaptoethanol (1.75 µl/500 ml media) and 10% FBS.
  4. Centrifuge at 900 x g for 5 min at 4 °C and resuspend all cells in 30 ml media. Add 5 ml media/well in a 6-well plate and incubate for 7 days at 37 °C and 5% CO2.
  5. Following the 7 day incubation, discard media, wash adherent cells with 5 ml warm PBS and add 5 ml fresh media to each well. Allow cells to grow to confluency (approximately 5 - 7 days), trypsinize, pool all cells, and passage as described in step 4.6. Re-plate cells to 6-well plate. Repeat this step three times.
  6. After three passages, allow cells to grow to confluency, wash wells three times with PBS and add 2 ml/well of DMEM:F12 + 1x concentrated mitogen supplement and penicillin (50 µg /ml)/streptomycin (50 µg/ml), ensuring that this media is free of FBS. Collect lymph node-conditioned media after 72 hr, pool, aliquot, and store at -80 °C until use.
  7. If desired, confirm the phenotype of the isolated lymph node stromal cells (LNSC) using antibodies against mouse CD45 and gp38, using standard flow cytometry techniques as described previously13.

6. Use of Organ-conditioned Media for Downstream Assays Related to Metastatic Behavior of Cancer Cells

  1. Once the organ-conditioned media has been generated as described in steps 1 - 5, use it to carry out different downstream cell and molecular biology assays in order to determine the influence of soluble organ-derived factors on the metastatic behavior of cancer cells. Examples of standard assays (described elsewhere in the literature) include protein arrays13, cellular growth assays13, cellular migration assays13, tumorsphere formation14, and RT-PCR15. The original base media used to generate the organ-conditioned media (i.e., unconditioned DMEM:F12 media supplemented with 1x concentrated mitogen supplement and penicillin (50 µg/ml)/streptomycin (50 µg/ml) should be used as a negative control.

Results

Generation of Organ-conditioned Media

An overview diagram/schematic of the process of organ isolation and generation of conditioned media is presented in Figure 1, with representative photographic images of the procedure shown in Figure 2. It should be noted that when this protocol was first under development, liver was included in our analysis because it is a common site of bre...

Discussion

Metastasis is a complex process by which a series of cellular events are ultimately responsible for tissue invasion and distant tumor establishment4,30,31. The ex vivo model system presented here can be utilized to study two important aspects of metastatic progression: cancer cell homing or migration to a specific organ ("getting there") and growth in that organ ("growing there"). Many studies have previously focused on identifying key molecular characteristics associated with the canc...

Disclosures

The authors declare that they have no competing financial interests.

Acknowledgements

This work was supported by grants from the Canadian Breast Cancer Foundation-Ontario Region, the Canada Foundation for Innovation (No. 13199), and donor support from John and Donna Bristol through the London Health Sciences Foundation (to A.L.A.). Studentship and fellowship support were provided by the Ontario Graduate Scholarship program (Province of Ontario, to G.M.P. and J.E.C.), the Canada Graduate Scholarship-Master's program (to M.M.P), the Canadian Institutes of Health Research (CIHR)-Strategic Training Program (to M.M.P., G.M.P and J.E.C.) and the Pamela Greenaway-Kohlmeier Translational Breast Cancer Research Unit at the London Regional Cancer Program (to M.M.P., G.M.P., J.E.C. and Y.X.). A.L.A. is supported by a CIHR New Investigator Award and an Early Researcher Award from the Ontario Ministry of Research and Innovation.

Materials

NameCompanyCatalog NumberComments
50 ml conical tubesThermo Scientific (Nunc)339652Keep sterile
1x Phosphate-buffered salineThermoFisher Scientific10010-023Keep sterile
Nude miceHarlan LaboratoriesHsd:Athymic Nude-Foxn1nuUse at 6 - 12 weeks of age
Polystyrene foam padN/AN/AThe discarded lid (~ 4 x 8 inches or larger) of a polystyrene foam shipping container can be used for this purpose. Sterilize by wiping with ethanol.
ForcepsFine Science Tools11050-10Keep sterile
ScissorsFine Science Tools14058-11Keep sterile
Gauze padsFisher Scientific22-246069Keep sterile
60 mm2 glass petri dishesSigma-AldrichCLS7016560Keep sterile
Scalpel bladesFisher ScientificS95937AKeep sterile
DMEM:F12Life Technologies21331-020Warm in 37 °C water bath before use, keep sterile 
1x Mito + Serum ExtenderBD Biosciences355006Referred to as "concentrated mitogen supplement" in the manuscript. Keep sterile
Penicillin-Streptomycin (10,000 U/ml)Life Technologies15140-122Keep sterile
Rosewell Park Memorial Institute 1640 (RPMI 1640)Life Technologies11875-093Warm in 37 °C water bath before use, keep sterile 
Fetal Bovine SerumSigma-AldrichF1051-500MLKeep sterile
Trypsin/EDTA solutionThermoFisher ScientificR-001-100Warm in 37 °C water bath before use, keep sterile 
6-well tissue culture platesThermo Scientific (Nunc)140675Keep sterile
0.22 μm syringe filtersSigma-AldrichZ359904Keep sterile
T75 tissue culture flasksThermo Scientific (Nunc)178905Keep sterile
TranswellsSigma-AldrichCLS3464Keep sterile, use for migration assays
Anti-mouse Sca-1R&D SystemsFAB1226Puse at 10 µl/106 cells
Anti-mouse CD105R&D SystemsFAB1320Puse at 10 µl/106 cells
Anti-mouse CD29R&D SystemsFAB2405P-025use at 10 µl/106 cells
Anti-mouse CD73R&D SystemsFAB4488Puse at 10 µl/106 cells
Anti-mouse CD44R&D SystemsMAB6127-SPuse at 0.25 µg/106 cells
Anti-mouse CD45eBioscience11-0451-81use at 5 µl/106 cells
Anti-mouse gp38eBioscience12-5381-80use at 10 µl/106 cells
β-mercaptoethanol Sigma-AldrichM6250 Keep sterile
Protein arraysRayBiotech Inc.AAM-BLM-1-2Use 1 array per media condition (including negative control), in triplicate

References

  1. Siegel, R. L., Miller, K. D., Jemal, A. Cancer statistics, 2015. CA Cancer J Clin. 65 (1), 5-29 (2015).
  2. Fidler, I. J. The organ microenvironment and cancer metastasis. Differentiation. 70 (9-10), 498-505 (2002).
  3. Chambers, A. F., Groom, A. C., MacDonald, I. C. Dissemination and growth of cancer cells in metastatic sites. Nat Rev Cancer. 2 (8), 563-572 (2002).
  4. Kennecke, H., et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 28 (20), 3271-3277 (2010).
  5. Nguyen, D. X., Bos, P. D., Massague, J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 9 (4), 274-284 (2009).
  6. Ewing, J. Neoplastic Diseases: A Treatise on Tumors. Am J Med Sci. 176 (2), 278 (1928).
  7. Paget, S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8 (2), 98-101 (1989).
  8. Weiss, L. Comments on hematogenous metastatic patterns in humans as revealed by autopsy. Clin Exp Metastasis. 10 (3), 191-199 (1992).
  9. Bos, P. D., et al. Genes that mediate breast cancer metastasis to the brain. Nature. 459 (7249), 1005-1009 (2009).
  10. Kang, Y., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell. 3 (6), 537-549 (2003).
  11. Minn, A. J., et al. Genes that mediate breast cancer metastasis to lung. Nature. 436 (7050), 518-524 (2005).
  12. Chu, J. E., et al. Lung-Derived Factors Mediate Breast Cancer Cell Migration through CD44 Receptor-Ligand Interactions in a Novel Ex Vivo System for Analysis of Organ-Specific Soluble Proteins. Neoplasia. 16 (2), (2014).
  13. Deepak, S., et al. Real-Time PCR: Revolutionizing Detection and Expression Analysis of Genes. Curr Genomics. 8 (4), 234-251 (2007).
  14. Hammerschmidt, S. I., et al. Stromal mesenteric lymph node cells are essential for the generation of gut-homing T cells in vivo. J Exp Med. 205 (11), 2483-2490 (2008).
  15. Dominici, M., et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 8 (4), 315-317 (2006).
  16. Baddoo, M., et al. Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. J Cell Biochem. 89 (6), 1235-1249 (2003).
  17. Furger, K. A., Menon, R. K., Tuck, A. B., Bramwell, V. H., Chambers, A. F. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med. 1 (5), 621-632 (2001).
  18. Radisky, E. S., Radisky, D. C. Matrix metalloproteinases as breast cancer drivers and therapeutic targets. Front Biosci (Landmark Ed). 20, 1144-1163 (2015).
  19. Radisky, E. S., Radisky, D. C. Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer. J Mammary Gland Biol Neoplasia. 15 (2), 201-212 (2010).
  20. Radisky, E. S., Radisky, D. C. Stromal induction of breast cancer: inflammation and invasion. Rev Endocr Metab Disord. 8 (3), 279-287 (2007).
  21. Kakinuma, T., Hwang, S. T. Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol. 79 (4), 639-651 (2006).
  22. Zlotnik, A. Chemokines and cancer. Int J Cancer. 119 (9), 2026-2029 (2006).
  23. Schlesinger, M., Bendas, G. Vascular cell adhesion molecule-1 (VCAM-1)--an increasing insight into its role in tumorigenicity and metastasis. Int J Cancer. 136 (11), 2504-2514 (2015).
  24. Cook, K. L., Shajahan, A. N., Clarke, R. Autophagy and endocrine resistance in breast cancer. Expert Rev Anticancer Ther. 11 (8), 1283-1294 (2011).
  25. Singh, P., Alex, J. M., Bast, F. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Med Oncol. 31 (1), 805 (2014).
  26. Lee, S. H., Jeong, D., Han, Y. S., Baek, M. J. Pivotal role of vascular endothelial growth factor pathway in tumor angiogenesis. Ann Surg Treat Res. 89 (1), 1-8 (2015).
  27. Erdmann, R. B., Gartner, J. G., Leonard, W. J., Ellison, C. A. Lack of functional TSLP receptors mitigates Th2 polarization and the establishment and growth of 4T1 primary breast tumours but has different effects on tumour quantities in the lung and brain. Scand J Immunol. 78 (5), 408-418 (2013).
  28. Chambers, A. F., et al. Steps in tumor metastasis: new concepts from intravital videomicroscopy. Cancer Metastasis Rev. 14 (4), 279-301 (1995).
  29. Chiang, A. C., Massague, J. Molecular basis of metastasis. N Engl J Med. 359 (26), 2814-2823 (2008).
  30. Gupta, G. P., et al. Identifying site-specific metastasis genes and functions. Cold Spring Harb Symp Quant Biol. 70, 149-158 (2005).
  31. Frantz, C., Stewart, K. M., Weaver, V. M. The extracellular matrix at a glance. J Cell Sci. 123, 4195-4200 (2010).
  32. Price, A. P., England, K. A., Matson, A. M., Blazar, B. R., Panoskaltsis-Mortari, A. Development of a decellularized lung bioreactor system for bioengineering the lung: the matrix reloaded. Tissue Eng Part A. 16 (8), 2581-2591 (2010).
  33. Bonnans, C., Chou, J., Werb, Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol. 15 (12), 786-801 (2014).
  34. Hynes, R. O. The extracellular matrix: not just pretty fibrils. Science. 326 (5957), 1216-1219 (2009).
  35. Psaila, B., Lyden, D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer. 9 (4), 285-293 (2009).
  36. Lee, R. H., Oh, J. Y., Choi, H., Bazhanov, N. Therapeutic factors secreted by mesenchymal stromal cells and tissue repair. J Cell Biochem. 112 (11), 3073-3078 (2011).

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Explore More Articles

Organ conditioned MediaOrgan specific FactorsBreast Cancer MetastasisLymph NodesLungsBonesBrainEx Vivo PlatformMouse ModelTissue HarvestingOrgan Isolation

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved